Development of Sedative Dexmedetomidine Sublingual In Situ Gels: In Vitro and In Vivo Evaluations

• Main Authors: Ayat A. Allam (Author), Nermin E. Eleraky (Author), Nadeen H. Diab (Author), Mahmoud Elsabahy (Author), Sahar A. Mohamed (Author), Hala S. Abdel-Ghaffar (Author), Nivin A. Hassan (Author), Samia A. Shouman (Author), Mervat M. Omran (Author), Sahar B. Hassan (Author), Noura G. Eissa (Author)
• Format: Book
• Published: MDPI AG, 2022-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Intravenous dexmedetomidine (DEX) is currently approved by the FDA for the sedation of intubated patients in intensive care units to reduce anxiety and to augment postoperative analgesia. Bradycardia and hypotension are limitations associated with the intravenous administration of DEX. In this study...